The Share

The Diamyd Medical share is traded on Nasdaq First North Growth Market (ticker : DMYD B). ISIN code: SE0005162880.

About Nasdaq First North Growth Market

Nasdaq First North Growth Market is an alternative marketplace operated by an exchange within the Nasdaq Group. Companies on Nasdaq First North Growth Market are not subject to the same rules as companies on the regulated main market. Instead they are subject to a less extensive set of rules and regulations adjusted to small growth companies. The risk in investing in a company on Nasdaq First North Growth Market may therefore be higher than investing in a company on the main market. All companies with shares traded on Nasdaq First North Growth Market have a Certified Adviser who monitors that the rules are followed. The Exchange approves the application for admission to trading.

Certified Adviser at Nasdaq First North Growth Market

FNCA Sweden AB, Humlegårdsgatan 5, Box 5807, SE-102 48 Stockholm. Tel: 08-528 00 399, E-mail: info@fnca.se.

Analysts

Analysts following Diamyd Medical:
Johan Lochen, Erik Penser Bank. Phone: +46 8 463 80 00. Erik Penser Bank equity research

Felicia Rittemar, Vator Securities, Phone: +46 8 5333 2737. Vator Securities equity research

Annual Report

  December 22, 2020

Company Presentation

 June 23, 2021
  Annual Report 20/21, November 11, 2021

Dear Shareholders and readers

In a changing world that at the time of writing is finding its way out of the largest pandemic in modern times, Diamyd Medical is standing strong. We have built an organization that is less dependent on external help to conduct the work around clinical trials, regulatory strategy, and analysis of data. We are establishing our proprietary manufacturing to ensure long-term access to the active component of our therapeutic diabetes vaccine Diamyd® when it is time for commercialization....

We have convincing safety data and strong efficacy data that show that precision medicine is the way forward in diabetes and for our diabetes vaccine.
Ulf Hannelius, President and CEO

Calendar

  
Data pager
Data pager
12
December 6 − December 11, 2021
IDF Virtual Congress 2021
International Diabetes Federation Virtual Congress
January 26 − January 27, 2022
5th Antigen-Specific Immune Tolerance Summit
January 26, 2022
Quarterly Report I
Quarterly Report 1 2021/2022
March 30, 2022
Quarterly Report II
Quarterly Report 2 2021/2022
 

We are dedicated to finding a cure for autoimmune diabetes through pharmaceutical development and investments in medical and stem cell technologies

 

Ten largest shareholders as of July 31, 2021

ShareholderA SharesB SharesCapital %Votes %
Avanza Pension 9 379 870 13.11 9.92
Essen-Möller, Anders 2 556 223 5 323 040 11.01 32.66
Lindkvist, Bertil 6 227 800 8.70 6.58
Nordnet Pension 2 564 507 3.58 2.71
Swedbank Försäkring 728 703 1.02 0.77
Konstruktions o Försäljningsaktiebolag 725 000 1.01 0.77
Arandi Development AB 512 000 0.72 0.54
Relbo AB 475 550 0.66 0.50
Maria-Teresa Essen-Möller 463 998 0.65 0.49
Lindberg, Mikael 460 460 0.65 0.49
Remaining shareholders 42 152 645 58.90 44.57
Total 2 556 223 69 013 573 100.0 100.0

Order GAD for preclinical research

GAD PRODUCTS